)
CelLBxHealth (CLBX) investor relations material
CelLBxHealth Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 new business rose threefold YoY to £0.3m; 9M cash operating loss fell 60% to £4.0m, while FY 2026 revenue guidance was revised to ~£1.8m due to timing effects from operational realignment.
FY 2027 revenue is expected to reach £3.0m–£4.0m, supported by stronger commercial momentum, an expanding pipeline and operational improvements.
Financial highlights
Q3 revenue booked was £0.2m; new business secured was £0.3m versus £0.1m in Q3 2025.
9M cash operating loss decreased 60% YoY to £4.0m from £9.7m; cash and cash equivalents were £1.4m at 30 September 2026.
FY 2026 revenue is expected at ~£1.8m, up 29% YoY from £1.4m in FY 2025; a further £0.1m of business was secured in early October.
Outlook and guidance
Q4 investment in growth, product and service optimisation, and new product development is expected to raise average monthly cash expenditure by £0.1m from Q3's £0.4m cash burn.
Following receipt of the anticipated £0.8m R&D tax credit, cash runway is expected to extend through Q1 2027.
FY 2027 revenue guidance is £3.0m–£4.0m, reflecting anticipated commercial momentum, pipeline expansion and benefits of 2026 operational improvements.
- Q2 revenue doubled and cost base was cut, but funding beyond Q2 2027 remains uncertain.CLBX
H1 2026 - Restructuring and key partnerships set the stage for strong revenue growth and EBITDA targets.CLBX
H2 2025 - Restructuring and cost cuts drive a projected 50% revenue increase for FY 2026.CLBX
Q1 2026 TU - FY2025 revenue was £1.4M, with cost cuts and partnerships driving targeted FY26 growth.CLBX
Q4 2025 TU - Fundraise, restructuring, and partnerships drive CTC diagnostics growth and target 2028 profitability.CLBX
Investor Update - Revenue fell to £0.8m, but cost controls and new contracts support growth and cash runway into 2026.CLBX
H1 2025 - Large pharma contracts and cost controls set the stage for growth and cashflow positive trading by 2026.CLBX
H1 2024 - Revenue doubled and losses narrowed as commercial momentum builds and cash runway extends.CLBX
H2 2023 - Patented blood test isolates living tumor cells, enabling earlier, more precise cancer care.CLBX
Emerging Growth Conference 79
)
)
)
)
)
)
)
)